252 related articles for article (PubMed ID: 12187957)
21. Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization.
Nishizaki T; Kubota H; Harada K; Harada K; Ito H; Suzuki M; Sasaki K
Hum Pathol; 2000 May; 31(5):608-14. PubMed ID: 10836301
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.
Lee D; Suh YL; Park TI; Do IG; Seol HJ; Nam DH; Kim ST
J Surg Oncol; 2013 May; 107(6):646-52. PubMed ID: 22926763
[TBL] [Abstract][Full Text] [Related]
23. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
Montgomery RM; Queiroz Lde S; Rogerio F
Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
[TBL] [Abstract][Full Text] [Related]
24. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme.
Stark AM; Hugo HH; Witzel P; Mihajlovic Z; Mehdorn HM
Zentralbl Neurochir; 2003; 64(1):30-6. PubMed ID: 12582944
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
26. [Immunohistochemical study of the expression of proliferating cell nuclear antigen in astrocytic gliomas of the cerebral hemispheres].
Korshunov AG; Sycheva RV
Arkh Patol; 1996; 58(2):32-7. PubMed ID: 8712938
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
28. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
29. Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors.
Bian XW; Shi JQ; Liu FX
Anal Quant Cytol Histol; 2000 Dec; 22(6):429-37. PubMed ID: 11147296
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of p53 protein expression in glioblastoma.
Birner P; Piribauer M; Fischer I; Gatterbauer B; Marosi C; Ungersböck K; Rössler K; Budka H; Hainfellner JA
Oncol Rep; 2002; 9(4):703-7. PubMed ID: 12066196
[TBL] [Abstract][Full Text] [Related]
31. Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.
Korshunov A; Golanov A
J Neurooncol; 2001 Mar; 52(1):63-72. PubMed ID: 11451204
[TBL] [Abstract][Full Text] [Related]
32. The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis.
Ribeiro Mde C; Coutinho LM; Hilbig A
Arq Neuropsiquiatr; 2004 Jun; 62(2A):262-70. PubMed ID: 15235729
[TBL] [Abstract][Full Text] [Related]
33. Biomarker-based prognostic stratification of young adult glioblastoma.
Zhang RQ; Shi Z; Chen H; Chung NY; Yin Z; Li KK; Chan DT; Poon WS; Wu J; Zhou L; Chan AK; Mao Y; Ng HK
Oncotarget; 2016 Jan; 7(4):5030-41. PubMed ID: 26452024
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of neuronal marker expression in glioblastomas.
Lee KH; Kang KJ; Moon KS; Jung TY; Jung S; Kim JH; Kim HS; Lee MC
Childs Nerv Syst; 2012 Nov; 28(11):1879-86. PubMed ID: 22922887
[TBL] [Abstract][Full Text] [Related]
35. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients.
Ganigi PM; Santosh V; Anandh B; Chandramouli BA; Sastry Kolluri VR
Pediatr Neurosurg; 2005; 41(6):292-9. PubMed ID: 16293948
[TBL] [Abstract][Full Text] [Related]
37. Higher pAkt expression predicts a significant worse prognosis in glioblastomas.
Suzuki Y; Shirai K; Oka K; Mobaraki A; Yoshida Y; Noda SE; Okamoto M; Suzuki Y; Itoh J; Itoh H; Ishiuchi S; Nakano T
J Radiat Res; 2010; 51(3):343-8. PubMed ID: 20410674
[TBL] [Abstract][Full Text] [Related]
38. [Morphological classification of glioblastomas].
Figarella-Branger D; Bouvier C; Moroch J; Michalak S; F Burel-Vandenbos
Neurochirurgie; 2010 Dec; 56(6):459-63. PubMed ID: 20864138
[TBL] [Abstract][Full Text] [Related]
39. Inducible cyclooxygenase (COX-2) in glioblastoma--clinical and immunohistochemical (COX-2-VEGF) correlations.
Buccoliero AM; Caldarella A; Gheri CF; Taddei A; Paglierani M; Pepi M; Mennonna P; Taddei GL
Clin Neuropathol; 2006; 25(2):59-66. PubMed ID: 16550738
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of angiopoietin-like protein 3 expression in patients with glioblastoma.
Wang PF; Li HL; Qi X; Yao K; Han S; Liu N; Yang YK; Li SW; Yan CX
Neoplasma; 2016; 63(1):93-8. PubMed ID: 26639238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
